Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037512 | 1.00 | ADRB2 (0.56) | ADRB2ADRB3 | |
| SCHEMBL2451871 | 0.92 | ADRB2 (0.55) | ADRB2ADRB3 | |
| SCHEMBL2451868 | 0.92 | ADRB2 (0.55) | ADRB2ADRB3 | |
| SCHEMBL5043908 | 0.90 | ADRB2 (0.57) | ADRB2ADRB3 | |
| SCHEMBL5043906 | 0.90 | ADRB2 (0.57) | ADRB2ADRB3 | |
| SCHEMBL14204726 | 0.89 | ADRB2 (0.55) | ADRB2ADRB3 | |
| SCHEMBL14204704 | 0.88 | ADRB2 (0.54) | ADRB2ADRB3 | |
| SCHEMBL5038655 | 0.87 | ADRB2 (0.46) | ADRB2ADRB3 | |
| SCHEMBL5038654 | 0.87 | ADRB2 (0.46) | ADRB2ADRB3 | |
| SCHEMBL5140719 | 0.86 | ADRB2 (0.47) | ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885ADRB3 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.